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Abstract
The endocannabinoid anandamide (AEA) is an antinociceptive lipid that is inactivated through cellular uptake and
subsequent catabolism by fatty acid amide hydrolase (FAAH). Fatty acid binding proteins (FABPs) are intracellular carriers
that deliver AEA and related N-acylethanolamines (NAEs) to FAAH for hydrolysis. The mammalian brain expresses three
FABP subtypes: FABP3, FABP5, and FABP7. Recent work from our group has revealed that pharmacological inhibition of
FABPs reduces inflammatory pain in mice. The goal of the current work was to explore the effects of FABP inhibition upon
nociception in diverse models of pain. We developed inhibitors with differential affinities for FABPs to elucidate the
subtype(s) that contributes to the antinociceptive effects of FABP inhibitors. Inhibition of FABPs reduced nociception
associated with inflammatory, visceral, and neuropathic pain. The antinociceptive effects of FABP inhibitors mirrored their
affinities for FABP5, while binding to FABP3 and FABP7 was not a predictor of in vivo efficacy. The antinociceptive effects of
FABP inhibitors were mediated by cannabinoid receptor 1 (CB1) and peroxisome proliferator-activated receptor alpha
(PPARa) and FABP inhibition elevated brain levels of AEA, providing the first direct evidence that FABPs regulate brain
endocannabinoid tone. These results highlight FABPs as novel targets for the development of analgesic and anti-
inflammatory therapeutics.
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Introduction
Fatty acid binding proteins (FABPs) comprise a family of small
cytoplasmic lipid transport proteins [1]. FABPs are expressed in
numerous tissues, including the central and peripheral nervous
systems [2–6] and bind to a subset of endogenous ligands including
fatty acids, retinoic acid, and N-acylethanolamines (NAEs) [7–10].
The endocannabinoid anandamide (AEA) is an NAE that activates
cannabinoid receptors (CB) while palmitoylethanolamide (PEA)
and oleoylethanolamide (OEA) signal through nuclear peroxisome
proliferator-activated receptor alpha (PPARa) [11–13].
FABPs regulate a plethora of physiological processes including
lipid metabolism, neurite outgrowth, inflammation, sleep, and
neuronal signaling [14–20]. Consequently, modulation of FABP
function may hold therapeutic promise for the treatment of diverse
disorders. Indeed, genetic or pharmacological inhibition of FABPs
protects against atherosclerosis, diet induced obesity, experimental
autoimmune encephalomyelitis and ameliorates dyslipidemias
[20–22]. These effects are mediated through distinct targets
including kinases, PPAR gamma, and through attenuation of pro-
inflammatory cytokine release [20,23–25].
We have previously demonstrated that FABP5 and FABP7 are
capable of binding to NAEs including AEA and OEA and regulate
their signaling and catabolism by fatty acid amide hydrolase
(FAAH), the principal NAE hydrolyzing enzyme in mice [8,9,26].
Previous work has established that inhibition of FAAH potentiates
NAE signaling at CB1, CB2, and PPARa receptors and produces
antinociceptive and anti-inflammatory effects in models of visceral,
inflammatory, and neuropathic pain [26–29]. Similar effects are
observed following inhibition of monoacylglycerol lipase, the
major enzyme that hydrolyzes the endocannabinoid 2-arachido-
noylglycerol (2-AG) [30]. These data indicate that targeting
endocannabinoids and NAEs may offer a therapeutic avenue for
the treatment of pain and inflammation.
Recently, we developed a novel a-truxillic acid-based FABP
inhibitor termed SBFI26 and demonstrated that pharmacological
FABP inhibition reduced nociception and inflammation in the
formalin and carrageenan models of pain [31]. Here, we evaluate
three new analogs based on SBFI26 to determine how inhibition
across FABP3, FABP5, and FABP7 would reduce nociception
associated with models of visceral, inflammatory, and neuropathic
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pain. Furthermore, we examined the role of CB and PPARa
receptors in these processes and determined whether FABP
inhibition elevates NAE and endocannabinoid levels in mouse
brain.
Materials and Methods
Ethics Statement
The experiments conducted herein conform to the National
Institutes of Health Guidelines for the Care and Use of Laboratory
Animals and were approved by the Stony Brook University
Institutional Animal Care and Use Committee (IACUC #2011-
1834).
Chemicals
12-NBD-stearate [12-N-methyl-(7-nitrobenz-2-oxa-1,3-diazo)
aminostearicacid] was from Avanti Polar Lipids (Alabaster, AL).
PEA, d4-PEA, OEA, d2-OEA, 2-AG and d5-2-AG were from
Cayman Chemical (Ann Arbor, MI). AEA and d4-AEA were from
R&D systems. [14C]AEA (arachidonoyl-[1-14C]ethanolamide,
60 mCi/mmol) was provided by the Drug Supply Program at
the National Institute on Drug Abuse while [3H]2-oleoylglycerol
([3H]2-OG) was purchased from Perkin Elmer. Acetonitrile,
chloroform, and methanol were of the highest possible purity
and were obtained from Fisher Scientific.
Synthesis of SBFI26, SBFI50, SBFI60, and SBFI62
Synthesis of SBFI26 (alpha-2,4-diphenylcyclobutane-1,3-
dicarboxylic acid mono-1-naphthyl ester). Alpha-truxillic
acid (297 mg, 1.0 mmol) was suspended in thionyl chloride
(3 mL), and one drop of DMF was added to the suspension.
The reaction mixture was heated to reflux for 3 h. The excess
thionyl chloride and DMF was removed in vacuo and truxillic acyl
chloride was obtained, which was used directly in the subsequent
reaction. To the solution of truxillic acyl chloride in THF (10 mL)
was added drop wise the solution of 1-naphthol (120 mg,
0.84 mmol) in THF (5 mL) and pyridine (0.5 mL), and the
reaction mixture was heated to reflux for 3 h. The reaction was
quenched with addition of water (2 mL). The resulted solution was
diluted with ethyl acetate (15 mL) and the aqueous layer was
separated. The organic layer was dried over MgSO4 and
concentrated in vacuo. The crude product was purified by flashed
column chromatography on silica gel using ethyl acetate/hexanes
(10% R 25%) as eluent to afford alpha-truxillic acid mono-1-
naphthyl ester as white solid (202 mg, 57%): m.p.: 192–193 uC; 1H
NMR (300 MHz, (CD3)2CO) d 4.15 (dd, J= 10.4, 7.0 Hz, 1H),
4.56 (dd, J= 10.4, 7.0 Hz, 1H), 4.75–4.68 (m, 2H), 6.42 (d,
J = 7.5 Hz, 1H), 7.65–7.24 (m, 15H), 7.72 (d, J= 8.2 Hz, 1H); 13C
NMR (300 MHz, (CD3)2CO) d 41.650, 42.119, 45.416, 46.766,
117.932, 121.361, 125.251, 125.678, 126.270, 126.724, 126.849,
126.921, 127.396, 127.629, 127.826, 128.245, 128.271, 128.490,
128.754, 129.055, 134.473, 139.456, 170.680, 172.139; HRMS
(ES) m/z calculated for C28H22O4 + NH4 (M + NH4)+: 440.1862,
found 440.1856 (D -1.2 ppm).
Synthesis of SBFI50 (alpha-2,4-diphenylcyclobutane-1,3-
dicarboxylic acid mono-2-naphthyl ester). Alpha-truxillic
acid (297 mg, 1.0 mmol) was suspended in thionyl chloride
(3 mL), and one drop of DMF was added to the suspension.
The reaction mixture was heated to reflux for 3 h. The excess
thionyl chloride and DMF was removed in vacuo and truxillic acyl
chloride was obtained, which was used directly in the subsequent
reaction. To the solution of truxillic acyl chloride in THF (10 mL)
was added drop wise the solution of 2-naphthol (115 mg,
0.80 mmol) in THF (5 mL) and pyridine (0.5 mL), and the
reaction mixture was heated to reflux for 3 h. The reaction was
quenched with addition of water (2 mL). The resulted solution
was diluted with ethyl acetate (15 mL) and the aqueous layer was
separated. The organic layer was dried over MgSO4 and
concentrated in vacuo. The crude product was purified by flashed
column chromatography on silica gel using ethyl acetate/hexanes
(10% R 25%) as eluent to afford alpha-truxillic acid mono-2-
naphthyl ester as white solid (175 mg, 52%): m.p.: 204–206 uC; 1H
NMR (300 MHz, (CD3)2CO) d 4.15 (dd, J = 10.6, 7.2 Hz, 1H),
4.34 (dd, J= 10.6, 7.2 Hz, 1H), 4.71–4.58 (m, 2H), 6.58 (d,
J = 8.8 Hz, 1H), 6.84 (s, 1H), 7.61–7.26 (m, 12H), 7.78–7.70 (m,
2H), 7.86 (d, J = 8.0 Hz, 1H); 13C NMR (300 MHz, (CD3)2CO) d
41.295, 42.022, 46.043, 46.768, 118.430, 121.305, 125.596,
126.457, 126.909, 127.250, 127.294, 127.635, 127.808, 128.184,
128.264, 128,606, 128.870, 131.389, 133.634, 139.244, 139.349,
148.374, 170.656, 172.154; HRMS (ES) m/z calculated for
C28H22O4 + NH4 (M + NH4)+: 440.1864, found 440.1856 (D -
1.8 ppm).
Synthesis of SBFI60 (alpha-2,4-diphenylcyclobutane-1,3-
dicarboxylic acid mono-1-naphthyl amide). Alpha-truxillic
acid (150 mg, 0.51 mmol) was suspended in thionyl chloride
(3 mL), and one drop of DMF was added to the suspension. The
reaction mixture was heated to reflux for 3 h. The excess thionyl
chloride and DMF was removed in vacuo and truxillic acyl chloride
was obtained, which was used directly in the subsequent reaction.
To the solution of truxillic acyl chloride in THF (10 mL) was
added dropwise the solution of naphthyl-1-amine (36 mg,
0.25 mmol) in THF (5 mL) and pyridine (0.2 mL), and the
reaction mixture was heated to reflux for 3 h. The reaction was
quenched with addition of 1 M HCl solution (2 mL). The resulted
solution was diluted with ethyl acetate (15 mL) and the aqueous
layer was separated. The organic layer was dried over MgSO4 and
concentrated in vacuo. The crude product was crystallized from
ethyl acetate to afford alpha-truxillic acid mono-1-naphthyl amide
as white solid (72 mg, 68%): m.p.: 198–200 uC; 1H NMR
(300 MHz, (CD3)2SO) d 3.95 (dd, J= 10.4, 6.6 Hz, 1H), 4.20 (dd,
J = 10.4, 6.6 Hz, 1H), 4.44 (m, 2H), 7.07 (d, J= 7.4 Hz, 1H),
7.24–7.47 (m, 14H), 7.65 (d, J = 8.1 Hz, 1H), 7.83 (d, J = 8.1 Hz,
1H), 9.81 (s, 1H), 12.11 (s, 1H); 13C NMR (300 MHz, (CD3)2SO)
d 40.834, 42.202, 46.384, 47.840, 122.251, 123.442, 125.652,
125.756, 125.972, 126.280, 127.102, 127.166, 128.093, 128.211,
128.374, 128.435, 128.606, 128.701, 133.841, 133.950, 139.780,
140.511, 170.419, 173.592; HRMS (ES) m/z calculated for
C28H23NO3 + NH4 (M + NH4)+: 440.1862, found 440.1856 (D -
1.2 ppm).
Synthesis of SBFI62 (2,4-diphenylcyclobutane-1,3-
dicarboxylic acid di-1-naphthyl amide). Alpha-truxillic acid
(50 mg, 0.17 mmol) was suspended in thionyl chloride (1.5 mL),
and one drop of DMF was added to the suspension. The reaction
mixture was heated to reflux for 3 h. The excess thionyl chloride
and DMF was removed in vacuo and truxillic acyl chloride was
obtained, which was used directly in the subsequent reaction. To
the solution of truxillic acyl chloride in THF (10 mL) was added
dropwise the solution of naphthyl-1-amine (48 mg, 0.34 mmol) in
THF (3 mL) and pyridine (0.2 mL), and the reaction mixture was
heated to reflux for 3 h. The reaction was quenched with addition
of 1 M HCl solution (2 mL). The resulted solution was diluted
with ethyl acetate (15 mL) and the aqueous layer was separated.
The organic layer was dried over MgSO4 and concentrated in
vacuo. The crude product was crystallized from ethyl acetate to
afford alpha-truxillic acid di-1-naphthyl amide as white solid
(75 mg, 82%): m.p.: .240 uC; 1H NMR (300 MHz, (CD3)2SO) d
4.34 (t, J = 7.74 Hz, 2H), 4.65 (t, J= 7.74 Hz, 2H), 7.09 (d,
J = 7.4 Hz, 2H), 7.25–7.55 (m, 18H), 7.67 (d, J = 8.1 Hz, 2H),
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7.83 (d, J= 8.1 Hz, 2H) 9.87 (s, 2H); 13C NMR (300 MHz,
(CD3)2SO) d 41.358, 47.665, 122.340, 123.526, 125.656, 125.783,
125.972, 126.286, 127.155, 128.205, 128.473, 128.624, 128.674,
133.972, 140.425, 170.654; HRMS (ES) m/z calculated for
C38H30N2O2 + H (M+H)+:547.2386, found 547.2386 (D 0 ppm).
Drugs
SBFI26, SBFI50, SBFI60, and SBFI62 were synthesized as
described above. Rimonabant, SR144528, PF-3845, and naloxone
were kindly provided by the Drug Supply Program at the National
Institute on Drug Abuse. GW6471 was from Sigma. All drugs
were injected in a volume of 10 ml/g body weight.
Energy Scoring of SB-FI compounds with FABPs
Molecular mechanics-based interaction energy scores were
computed using DOCK version 6.6. An energy grid for FABP7
(PDB: 1FE3) was previously generated with 6–9 Lennard-Jones
exponents and at 0.3 A˚ resolution and re-docking of SBFI26 was
performed [31] using the standard DOCK flexible ligand (FLX)
protocol [32]. Additional target FABPs – FABP5 (PDB: 1B56), and
FABP3 (PDB: 3RSW) – were aligned to FABP7 in UCSF Chimera
[33] using protein backbone alpha-carbons resulting in RMSDs of
0.95 A˚ for FABP5 and 0.96 A˚ for FABP3, suggesting an overall
good alignment. Structures and mol2 files of the a-truxillic acid
analogs SBFI50, SBFI60, and SBFI62 were created from SBFI26
in UCSF Chimera preserving the binding pose from initial
docking to the FABP7 grid. All four SB-FI ligands were then
energy-minimized in each FABP pocket using parameters
consistent with the DOCK rigid ligand (RGD) protocol [32].
Energy minimizations were performed in Cartesian space and
with 6–12 Lennard-Jones exponents [34]. All calculations were
performed on a Dell PowerEdge T110 server running Ubuntu
version 12.04 and using an Intel quad-core CPU in the Rizzo
laboratory (Dept. of Applied Mathematics and Statistics, Stony
Brook University).
Binding of Inhibitors to FABPs
Inhibitory constant (Ki) values were elucidated utilizing NBD-
stearate fluorescence displacement as described previously [9,31].
The tests were performed in 96-well plates containing inhibitors
(0.1 – 50.0 mM), FABP, and NBD-stearate. Fluorescence intensity
was measured with a FLUOstar OPTIMA spectrofluorometer
with excitation and emission wavelengths of 460 and 544 nm,
respectively. Ki values were derived from nonlinear regression
analysis using the equation Ki = IC50/(1+([NBD-stearate]/Kd)).
Respective Kd values of 0.18, 0.16, and 0.22 mM for NBD-stearate
with FABP3, FABP5, and FABP7 were determined previously [9].
Enzyme Assays
AEA and 2-OG hydrolysis was determined using modified
protocols to those described previously [8,35]. Mice were injected
with inhibitors (20 mg/kg, i.p.) and the brains and livers were
harvested 60 min later. The tissue homogenates were subsequently
incubated with 30 mM [14C]AEA or 10 mM [3H]2-OG for
30 min. Reactions were stopped with two volumes of chloro-
form:methanol (1:1) and the methanol phase was counted using a
Beckman LS6500 scintillation counter.
Cytotoxicity
Cytotoxicity of the FABP inhibitors SBFI26 and BMS309403
were examined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5
diphenyl tetrazolium bromide] colorimetric assay. HeLa cells were
seeded into 96-well plates (15,000 cells/well) and incubated for
24 hours at 37uC in DMEM supplemented with 10% FBS,
penicillin (100 U/mL) and streptomycin (100 mg/mL). The cells
were subsequently washed with PBS and treated with serum-free
DMEM containing 10 nM to 1 mM SBFI26, BMS309403, or
5 mM hydrogen peroxide as a positive control. Following a 24 hr
incubation, the cells were washed with PBS and treated with MTT
(0.5 mg/mL in PBS) for 4 hrs. The cells were subsequently
solubilized using DMSO and the absorbance was read at 562 nm
in a microplate reader.
Animals
Male C57Bl/6 mice (22–30 g, Taconic Farms) or male Fischer
344 rats (250–350 g, Taconic Farms) were used for all exper-
iments. The animals were group housed at room temperature and
kept on a 12:12 hour light:dark cycle with ad libitum access to water
and food. The animals were habituated to the experimental room
for one day before testing and at least two hours before each
experiment. All experiments were approved by the Stony Brook
University Institutional Animal Care and Use Committee. Unless
otherwise stated, animals were euthanized with CO2 and
subsequently decapitated. The experimenter was blinded to the
treatment condition of each animal.
Carrageenan-induced Paw Edema and Thermal
Hyperalgesia
Paw edema was induced by injecting 1% l-carrageenan (20 ml,
in sterile saline) into the plantar surface of the left hind paw using a
30 gauge needle attached to a glass syringe (Hamilton Company).
Paw diameters were measured before carrageenan injection and 4
or 24 hours after injection using digital electronic calipers (Fisher)
and expressed to the nearest 6 0.01 mm. SBFI26, SBFI50,
SBFI60, and SBFI62 were dissolved in DMSO:cremophor-EL:sa-
line (4% DMSO:10% Cremophor-EL) and administered (20 mg/
kg, i.p.) 60 min prior to injection of carrageenan. Receptor
antagonists were injected 10 min before the inhibitors. Rimona-
bant and SR144528 (3 mg/kg, i.p.) were dissolved in ethanol:cre-
mophor-EL:saline (1:1:18) while GW6471 (4 mg/kg, i.p.) was
dissolved in DMSO:cremophor-EL:saline (2% DMSO:5% Cre-
mophor-EL). Edema is reported as the change in paw diameter at
24 hr compared to the baseline. Thermal hyperalgesia was
measured using the Hargreaves plantar apparatus (Ugo Basile)
as previously reported [31].
Formalin Test
Mice were habituated to the observation chamber (Plexiglas
box, 25 cm625 cm625 cm) for 30 min prior to formalin injec-
tion. Mice were administered FABP inhibitors 60 min prior to
formalin. The animals subsequently received an injection of
formalin (2.5% in saline, 20 ml) into the plantar surface of the right
hind paw using a 30 gauge needle and were immediately placed
back into the observation chamber and nocifensive behavior (time
spent licking or biting the paw) was recorded for 60 min.
Nocifensive behavior was scored during the first phase (0–5 min)
and the second phase (,15–45 min) of the formalin test.
Acetic acid-induced Writhing
Mice were acclimated to the laboratory environment for at least
two hours and were habituated to the testing chamber for 30 min
prior to acetic acid challenge. SBFI26, SBFI50, SBFI60, and
SBFI62 (20 mg/kg) were administered via the subcutaneous route
60 min before acetic acid. Rimonabant, SR144528, GW6471, and
naloxone were given 10 min before the inhibitors via the
subcutaneous route. The mice subsequently received an i.p.
FABP Inhibitors Reduce Pain and Elevate Brain Anandamide Levels
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injection of acetic acid (0.6% in sterile saline, 10 ml/g) and were
placed in observation chambers. Abdominal stretches (marked by
extension of the body and hind limbs) were counted for 20 min
starting at 5 min post-injection.
Locomotor Activity
Mice received injections of SBFI26 (20 mg/kg, i.p.) and 60 min
later were placed in an observation chamber (46625620 cm)
demarcated with 767 cm grids. Locomotor activity was recorded
for 5 min by a video camera suspended above the chamber and
subsequently scored by an observer blinded to the treatment
conditions. A grid crossing was scored when both hind legs of the
animal crossed the border of each grid square.
Rectal temperature
Rectal temperature was measured at baseline and 90 min
following vehicle or drug administration, by inserting a thermo-
couple probe 1.5 cm into the rectum and the temperature was
read using a thermocouple meter (Kent Scientific).
Rat neuropathic pain model
Male Fisher 344 rats were habituated and pre-injury evoked
responses were obtained. The Hargreaves test was used to assess
thermal hyperalgesia [36]. Briefly, plexiglass enclosures were set
atop a plexiglass platform and infrared source set at 50% power
located under the platform was used as the heat stimulus (Ugo
Basile). A 200 mW, 535 nm diode laser was mounted in an
adjustable stand placed beneath the plexiglass platform, and was
used as an alternative heat stimulus for some of the animals in this
study. The latency time to hind paw lift during heating of the
plantar surface was recorded. Five recordings were obtained on
each hind paw with at least 2 min rest between measurements.
The maximum time for exposure to the infrared or diode laser
source was 30.5 s to avoid any possible tissue injury. For
mechanical threshold measurements, the animal enclosures rested
on a screen with mesh of 0.5 cm spacing. Following acclimation,
an electronic von Frey Anesthesiometer (IITC Life Sciences) was
applied with increasing pressure to the plantar surface of the hind
paw until the animals lifted the hind paw. The number of grams of
force applied by the probe to induce withdrawal was recorded.
Five recordings were obtained on each hind paw with at least
3 min between measurements. For CCI surgeries, our procedure
closely followed that reported previously [37]. Briefly, each animal
received an i.p. injection of ketamine/xylazine (75 mg/kg and
10 mg/kg, respectively). The hind leg was surgically prepped and
the anesthetized animal placed prone on an sterile towel over a
heating pad. The temperature was monitored rectally. A skin
incision was made mid-thigh with a medium curved scalpel and
then scissors were used to expose the sciatic nerve. Approximately
1 cm of the main trunk proximal to the trifuraction was isolated
and 4 strands of 4-0 chromic gut were tied around the nerve ,
1 mm apart under magnification. In a modification of the original
method, a 2-0 prolene strand was placed between the nerve and
the gut to which the suture was tightened. The prolene strand was
then removed. This prevented over tightening and reduced
subsequent motor paralysis. The muscle layers were then
reopposed and sutured, and surgical staples were used to close
the skin. On post-injury days 7 through 10, heat and mechanical
measurements were obained for the ipsilateral hindpaw of each
CCI animal. Immediately following the post-injury measurements,
animals were randomized and received i.p. injections of vehicle or
20 mg/kg SBI26 (DMSO:cremophor:sterile saline 1:1:2 by
volume). Up to 0.8 ml of drug or vehicle was injected. The
observer was blinded as to administration of drug or vehicle.
Thermal and mechanical measurements were performed at 1 and
4 h post-injection. Data were normalized to pre-injury baseline
measurements for each animal.
Pharmacokinetics
Mice were injected with SBFI26 (20 mg/kg, i.p.) and were
subsequently rapidly euthanized by decapitation at the indicated
time points. The brain was rapidly removed and submerged in
liquid nitrogen while the blood was collected into a K2-EDTA
collection tube (Fisher). Plasma was isolated by centrifugation of
the blood and 50 ml of the plasma was combined with 150 ml
acetonitrile and centrifuged to remove the resulting protein pellet.
Subsequently, 50 ml of water was added to 50 ml of the
supernatant and 10 ml was injected for analysis into a Thermo
TSQ Quantum Access Triple Quadrupole mass spectrometer
(ThermoFisher). LC separation was achieved on a Luna C18
(15062 mm) column. Mobile phase A consisted of 100% H20
while mobile phase B was composed of 100% acetonitrile. The
flow rate was 200 ml/min. A linear gradient was used and started
at 50% B for 2 min, then ramped to 100% B in 8 min., with a
2 min hold at 100% B. The system was then equilibrated at 50%
B for a cycle time of 20 min. The mass spectrometer was operated
in the negative ion mode with the high voltage set at 23.5 kV.
The sheath pressure was 20 and the capillary was set to 270 uC.
Multiple reaction monitoring (MRM) was used with the transition
m/z 421 to 277 at 29 eV as the quantitation channel, while m/z
421 to 205 at 17 eV was employed as a conformation channel.
SBFI26 quantification was performed using an external calibration
curve.
Lipid Quantification
Quantification of endogenous NAEs and 2-AG were performed
as previously described with minor modifications [30]. Mice were
rapidly euthanized by decapitation and their brains flash frozen in
liquid nitrogen. The brains were subsequently thawed, weighed,
and homogenized in 8 ml of 2:1:1 CHCl3:MeOH:Tris (50 mM,
pH 8) in the presence of 4 ng d4-PEA, 4 ng d2-OEA, 400 pg d4-
AEA, and 40 ng d5-2-AG. Following centrifugation at 4uC, the
organic layer was removed and brought up to 8 ml with the same
buffer and centrifuged again. The resulting organic layer was dried
down with argon and resuspended with 100 ml of 2:1
CHCl3:MeOH and 10 ml was injected into the Thermo TSQ
Quantum Access Triple Quadropole mass spectrometer. LC
separation was achieved on a Gemini C18 (5062 mm65 mm)
equipped with a Gemini C18 SecurityGuard precolumn (4 mm
length 62 mm internal diameter). Mobile phase A consisted of
95:5% v:v H20:MeOH while mobile phase B was composed of
60:35:5 v:v:v i-PrOH:MeOH:H2O and quantification was per-
formed in the positive ion mode with the voltage set at 4 kV. 0.1%
formic acid was added to assist in ionization. The sheath pressure
was 30 and the capillary was set at 270 uC. The flow rate was
100 ml/min. The gradient started at 0% B and increased to 100%
B over 15 min followed by an isocratic gradient of 100% B for
10 min, and was equilibrated for 15 min at 0% B.
PPARa Transactivation Assay
PPARa activation was performed in HeLa cells as previously
described [9].
Statistical Analysis
Behavioral data are presented as means 6 S.E.M. of at least 6
animals per group. Statistical significance between vehicle,
inhibitor, and antagonist groups was determined using one-way
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ANOVA followed by Dunnett or Tukey post hoc analysis as
appropriate. For CCI measurements, the data were analyzed using
repeated measured ANOVA followed by Tukey post hoc analysis.
In all cases, differences of p,0.05 were considered significant.
Results
Design and in vitro Evaluation of FABP Inhibitors
The mammalian central nervous system expresses FABP3,
FABP5, and FABP7 [38]. In a recent publication [31], we showed
that pharmacological inhibition of FABPs with SBFI26, a
compound with a high affinity for FABP5 and FABP7 reduced
nociception in the formalin and carrageenan models of pain. To
begin identifying the FABP subtypes mediating such antinocicep-
tive effects, we designed three novel analogs of SBFI26 termed
SBFI50, SBFI60, and SBFI62 (Fig. 1A), that display differential
binding to FABP5 and FABP7. As an additional objective, the
inhibitors were designed to exhibit limited binding to FABP3
because ablation of this protein has been previously shown to
contribute to age-related cardiac hypertrophy [39].
SBFI50 was designed as a regioisomer of SBFI26 by coupling a
2-naphthol group with a-truxillic acid (Fig. 1A). In SBFI60, the
ester bond between the a-truxillic acid and the naphthyl group of
SBFI26 was replaced with an amide bond using naphthyl-1-amine.
Computational analysis through energy-minimization suggested
that although these three related inhibitors could be accommo-
dated in the different FABP pockets as suggested by similar
binding geometries (Fig. 1B), they would all possess higher
affinities for FABP7 relative to FABP5 or FABP3 (Table 1).
Encouragingly, these computational predictions showed a strong
correlation (Figure 1C) with experimentally measured binding
affinities (Table 2), suggesting the atomistic models employed in
these studies can be used to explore different structure activity
relationship series to optimize inhibitor potency.
Overall, compared to SBFI26, SBFI50 and SBFI60 possessed
lower experimental affinities for FABP5, retained high affinities for
FABP7, and were equally poor inhibitors of FABP3 (Table 2).
Unexpectedly, SBFI60 proved to be an extremely weak inhibitor
of FABP3 (Ki.10 mM), suggesting that this compound may
represent a novel scaffold for the design of future FABP5 and
FABP7 selective inhibitors. An additional inhibitor, a dinaphthy-
lamide analog of SBFI60 termed SBFI62 was also evaluated. Here,
both of the carboxylic acids of a-truxillic acid were fully
functionalized (Fig. 1A). Because SBFI62 lacks the free carboxylate
previously determined to be important for interaction affinity [31],
it was expected to exhibit low affinity across the FABP3, FABP5,
and FABP7 series. A series of energy minimizations for this analog
revealed that the added bulkier naphthylamide group would not
allow for a conserved binding geometry shared by the other three
inhibitors tested, which would similarly suggest lower affinity (data
not shown). Indeed, when tested experimentally, SBFI62 showed
much lower binding affinity for FABP5 and especially for FABP7
(Table 2).
FABP Inhibitors Produce Antinociceptive Effects
The antinociceptive effects of the FABP inhibitors were
examined using diverse models of nociception. In the carrageenan
model of inflammatory pain, SBFI26 and SBFI50 (20 mg/kg, i.p.)
reduced thermal hyperalgesia and paw edema while SBFI60 and
SBFI62 were without effect (Fig. 2A). In the formalin model of
inflammatory pain, SBFI26, SBFI50, and SBFI60 reduced the first
phase of nociception while SBFI26 also reduced the second phase
(Fig. 2B). Similar to the carrageenan model, SBFI62 was without
effect. The antinociceptive effects of FABP inhibitors were also
examined using the acetic acid writhing model of visceral pain.
SBFI26 significantly reduced writhing induced by acetic acid while
SBFI50, SBFI60, and SBFI62 were without effect (Fig. 2C). A dose
response analysis revealed that SBFI26 exhibited near maximal
efficacy at a dose of 20 mg/kg and increasing the dose did not
significantly enhance the antinociceptive effects of this compound
(Fig. 2D).
CB1 and PPARa Receptors Mediate the Antinociceptive
Effects of FABP Inhibitors
To examine the mechanism(s) mediating the analgesic effects of
FABP inhibitors, mice were pretreated with the CB1 antagonist
rimonabant, the CB2 antagonist SR144528, the PPARa antago-
nist GW6471, or the opioid receptor antagonist naloxone.
Treatment of mice with rimonabant completely blocked the
antinociceptive effects of SBFI26 in the acetic acid test (Fig. 2E),
indicating that CB1 receptors mediate the effects of SBFI26.
Rimonabant also blocked the antinociceptive effects of the FAAH
inhibitor PF-3845, which is known to produce CB1-mediated
analgesia by potentiating AEA signaling [40]. The antinociceptive
effects of SBFI26 were also blocked by the PPARa antagonist
Figure 1. Structures and binding affinities of FABP inhibitors. (A) Chemical structures of FABP inhibitors. (B) Superimposed models of SBFI26,
SBFI50, and SBFI60 in the binding pockets of FABP3, FABP5, and FABP7 reveal similar binding geometries. Amino acids lining the binding pockets are
shown with teal, gold, and grey representing FABP3, FABP5, and FABP7, respectively. (C) Correlation between binding affinities and energy scores of
SBFI26, SBFI50, and SBFI60 for FABP3, FABP5, and FABP7. Linear regression revealed an r2 value of 0.744. The binding affinities and energy scores are
derived from Table 1 and Table 2.
doi:10.1371/journal.pone.0094200.g001
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GW6471 (Fig. 2E). In contrast, antagonism of CB2 receptors with
SR144528 or opioid receptors with naloxone failed to reverse the
antinociceptive effects of SBFI26. As expected, administration of
the antagonists in the absence of SBFI26 did not alter nociceptive
responses.
FABP Inhibition Elevates Brain AEA Levels
The data presented thus far suggest that FABP inhibitors
produce analgesia by potentiating endocannabinoid/NAE signal-
ing. To examine this directly, we first determined the plasma and
brain levels of SBFI26. Following i.p. injection, plasma and brain
levels of SBFI26 peaked within one hour and gradually decreased
over time (Fig. 3A). The compound displayed a plasma and brain
half-life of approximately 3 hrs with levels returning to baseline by
24 hrs. As expected, the brain levels were lower than the plasma
levels.
The brain levels of PEA, OEA, AEA, and 2-AG were examined
following SBFI26 administration. Injection of SBFI26 significantly
elevated AEA levels while the levels of PEA, OEA, and 2-AG were
unaffected (Fig. 3B). SBFI26 did not inhibit AEA hydrolysis
(Fig. 3C), excluding the possibility that it elevates AEA levels by
inhibiting FAAH. Similar results were found with the other FABP
inhibitors. Furthermore, we have previously demonstrated that
SBFI26 does not activate CB1 [31], indicating that its antinoci-
ceptive effects do not stem from direct activation of CB1. This is
further supported by the inability of SBFI26 to reduce locomotor
activity or rectal temperature (Figs. 3D and 3E), effects that are
observed following administration of CB1 agonists [41,42].
Collectively, these data are the first to demonstrate that inhibition
of FABPs elevates brain AEA levels to produce analgesia.
FABP Inhibitors Reduce Thermal Hyperalgesia Associated
With Neuropathic Pain
To date, the antinociceptive effects of FABP inhibitors have
been investigated in models of inflammatory pain. To ascertain
whether FABP inhibitors reduce nociception associated with
neuropathic pain, SBFI26 was administered to rats subjected to
chronic constriction injury (CCI) of the sciatic nerve, a model of
neuropathic pain. As expected, CCI rats developed thermal
hyperalgesia and mechanical allodynia (Fig. 4A and B). Treatment
with SBFI26 completely reversed thermal hyperalgesia at 1 hr
post-administration with the effects persisting for up to 4 hrs
(Fig. 4A). In contrast, SBFI50, which exhibits lower affinity for
FABP5, was without effect (data not shown). Neither compound
altered mechanical thresholds (Fig. 4B and data not shown).
Discussion
Chronic pain affects approximately fifteen percent of the
population [43,44]. The endocannabinoid/NAE system has
emerged as a promising target for the development of pain
medications and cannabinoid receptor agonists have shown
therapeutic efficacy in patients suffering from peripheral neurop-
athies [45–47]. However, cannabinoid receptor agonists suffer
from untoward psychotropic effects [45,48], highlighting the need
to develop novel non-narcotic analgesics that lack the side-effects
and abuse potential of cannabinoid receptor agonists and other
clinically used analgesics.
Our group has recently identified FABPs as intracellular
endocannabinoid/NAE binding proteins [8,9]. Furthermore, we
have demonstrated that pharmacological inhibition of FABPs
produces antinociceptive effects that are mediated by cannabinoid
receptors [31], suggesting that FABP inhibitors may reduce
nociception by potentiating endocannabinoid signaling. To date,
a direct demonstration that FABPs regulate endocannabinoid
levels in vivo has not been reported. In addition, the development of
FABP inhibitors as antinociceptive and anti-inflammatory agents
requires demonstration of their broad efficacy in diverse models of
pain. Here, we sought to begin addressing both of these
outstanding questions.
In the current study, we show that inhibition of FABPs reduces
nociception in models of inflammatory, visceral, and neuropathic
pain. Of the inhibitors tested, SBFI26 was the most efficacious,
followed by SBFI50 and SBFI60, with SBFI62 completely lacking
efficacy. These results mirrored the experimental binding affinities
Table 1. Single-point energy calculations of inhibitors docked to FABPs.
Compound FABP3 FABP5 FABP7
(kcal/mol) (kcal/mol) (kcal/mol)
SBFI26 235.85 249.45 258.44
SBFI50 243.64 236.20 250.88
SBFI60 237.30 244.97 258.95
doi:10.1371/journal.pone.0094200.t001
Table 2. Binding affinities of SBFI26, SBFI50, SBFI60, and SBFI62 to FABPs.
Compound FABP3 FABP5 FABP7
Ki (mM) Ki (mM) Ki (mM)
SBFI26 3.960.7 0.960.1 0.460.0
SBFI50 3.560.3 1.360.2 0.660.1
SBFI60 .10 1.660.0 0.3 60.0
SBFI62 2.661.1 3.360.7 6.160.5
The Ki values represent averages 6 S.E. of three independent experiments.
doi:10.1371/journal.pone.0094200.t002
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in vivo
Figure 2. FABP inhibitors reduce nociception in models of inflammatory and visceral pain. (A) Effects of SBFI26, SBFI50, SBFI60, and
SBFI62 (20 mg/kg, i.p.) upon carrageenan-induced thermal hyperalgesia (left panel) and paw edema (right panel) in mice. *, p,0.05; **, p,0.01
versus carrageenan injected animals (black bar) (n = 6). (B) Effect of FABP inhibitors (20 mg/kg, i.p.) upon the first (left panel) and second phases (right
panel) of formalin-induced nociception in mice. *, p,0.05 versus vehicle control (n = 6). (C) SBFI26 reduces acetic acid-induced writhing in mice. **,
p,0.01 (n = 6). (D) Dose-response of SBFI26-mediated inhibition of acetic acid writhing in mice. **, p,0.01 (n = 6). (E) The antinociceptive effects of
SBFI26 are reversed by the cannabinoid receptor 1 antagonist rimonabant (SR1, 3 mg/kg) and the peroxisome proliferator-activated receptor alpha
antagonist GW6471 (4 mg/kg). In contrast, the cannabinoid receptor 2 antagonist SR144518 (SR2, 3 mg/kg) and the opioid antagonist naloxone
(2 mg/kg) were without effect. Rimonabant also reversed the antinociceptive effects of the FAAH inhibitor PF-3845 (blue bars). When administered
alone, the antagonists did not modulate nociception (green bars). *, p,0.05; **, p,0.01 versus vehicle control. ##, p,0.01; ###, p,0.001 versus
SBFI26 treated mice (n = 6–9).
doi:10.1371/journal.pone.0094200.g002
Figure 3. SBFI26 pharmacokinetics and its effect upon brain endocannabinoid levels. (A) Time course of SBFI26 levels in mouse plasma
(left panel) and brain (right panel) following a single injection (20 mg/kg, i.p.) (n = 5). (B) SBFI26 (20 mg/kg, i.p.) elevates brain levels of the AEA.
Tissues were harvested 90 min after SBFI26 administration. **, p,0.01 (n = 6). (C) Effect of FABP inhibitors (20 mg/kg, i.p.) upon AEA and 2-OG
hydrolysis by mouse brain and liver homogenates following a single injection (n = 3). (D) SBFI26 (20 mg/kg, i.p.) does not alter locomotor activity in
mice. Locomotor activity was measured 90 min after SBFI26 administration (n = 6). (E) SBFI26 (20 mg/kg, i.p.) does not reduce rectal temperature in
mice. Left graph: scatterplot of rectal temperatures at baseline and 90 min following injection of vehicle (black circles) or SBFI26 (red circles). Right
graph: change in rectal temperature between baseline and 90 min following administration of vehicle (white bar) or SBFI26 (red bar). Statistical
analysis was performed by paired t-test (p = 0.205) (n = 6).
doi:10.1371/journal.pone.0094200.g003
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of these compounds for FABP5 (Table 2), suggesting that high
affinity binding to this protein may underlie the antinociceptive
effects of FABP inhibitors. Indeed, SBFI50 and SBFI60, which
exhibit lower affinity for FABP5 compared to SBFI26, were
ineffective in the acetic acid test and similarly SBFI50 did not alter
nociception in the CCI model. Furthermore, SBFI26, SBFI50,
and SBFI60 bind to FABP7 with high affinity yet display markedly
different in vivo efficacies, indicating that inhibition of FABP7 is
unlikely to mediate the antinociceptive effects of these compounds.
Future experiments employing mice lacking subsets of FABPs will
be required to substantiate this hypothesis.
We have recently shown that AEA interacts with and is
transported by FABPs to FAAH for catabolism [8,9]. Indeed,
knockdown of FABP5 in cultured cells reduced AEA uptake and
hydrolysis [9]. Our current results are in agreement with these
studies and constitute the first direct observation that FABP
inhibition elevates brain AEA levels in vivo. Given that FABPs
exhibit a more restricted expression profile compared to the global
expression of FAAH in the brain [49], our data suggest that FABPs
may be major regulators of the AEA tone in a subset of brain
regions.
NAEs activate diverse receptor systems, including cannabinoid
and PPARa receptors [12,13]. In addition to AEA, FABPs bind to
other NAEs [9], suggesting that the antinociceptive effects
observed in FABP inhibitor treated mice may be mediated by
Figure 4. SBFI26 blocks thermal hyperalgesia in a rat model of neuropathic pain. (A) Thermal latencies and (B) mechanical thresholds in
rats subjected to CCI were measured following injection of 20 mg/kg SBFI26. SBFI26 was injected at the 0 hr time point and evoked behaviors were
measured at 1 and 4 hrs post-administration. The results are expressed as fraction of the pre-injury baseline measurement per animal (mean +/2
SEM). Pre-injury thermal latency was 23.5 +/2 0.7 s and mechanical threshold was 29.9 +/2 0.6 g (mean +/2 SEM). Results were analyzed by
repeated measures ANOVA followed by Tukey’s post-hoc analysis. *, p,0.05 versus 0 hr time point (n = 6).
doi:10.1371/journal.pone.0094200.g004
Figure 6. Cytotoxicity of SBFI26 and BMS309403 in HeLa cells.
Cells were incubated with the indicated compounds and viability was
assessed 24 hrs later. SBFI26 and BMS309403 reduced cell viability with
IC50 values of 31.164.1 mM and 11.360.9 mM, respectively (n = 3).
doi:10.1371/journal.pone.0094200.g006
Figure 5. Activation of PPARa by FABP inhibitors. HeLa cells
transfected with a PPARa reporter were incubated with the indicated
compounds for 6 hours and luciferase and b-galactosidase activities
were subsequently measured. Luciferase activity was normalized to b-
galactosidase. The blue line represents baseline PPARa activation in the
absence of agonists (n = 3).
doi:10.1371/journal.pone.0094200.g005
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NAEs that engage cannabinoid and/or PPARa receptors. Indeed,
our findings demonstrate the involvement of CB1 and PPARa
receptors. It is noteworthy that inhibition of FABPs did not elevate
PEA levels in mouse brains. Therefore, it is possible that the
PPARa-mediated antinociceptive effects may stem from elevated
PEA levels in peripheral nerves [29] or possibly in subsets of brain
regions that regulate nociception, such that local changes in PEA
levels may have eluded our analysis. Alternatively, FABPs may
regulate the signaling of a lipid distinct from PEA that engages
PPARa receptors. Lastly, it is unlikely that SBFI26 exerts its
antinociceptive effects by directly activating PPARa. Indeed, while
all four FABP inhibitors served as weak agonists at PPARa (Fig. 5),
only SBFI26 exerted significant antinociceptive effects, which
mirrors its higher affinity for FABP5.
Our findings also reveal that FABP inhibition modulates
thermal hyperalgesia but not mechanical allodynia in the CCI
model of neuropathic pain. Because heat and mechanical stimuli
can be gated by non-overlapping peripheral sensory neurons [50–
52], the selective modulation of heat sensitivity by FABPs may
result from their expression in heat sensitive fibers and possibly
their exclusion from mechanically-sensitive fibers. Alternatively, it
is possible that greater CNS penetration of FABP inhibitors is
required to modulate mechanical allodynia as reported for FAAH
inhibitors [28].
In conclusion, our findings demonstrate that FABP inhibitors
suppress nociception in multiple pain models, effects that are
mediated by both CB1 and PPARa receptors. Future medicinal
chemistry efforts will be aimed at enhancing the potency,
selectivity, and CNS penetration of FABP inhibitors. Because
SBFI26 exhibits lower cytotoxicity compared to the previously
described FABP inhibitor BMS309403 (Fig. 6) [53], inhibitors
built upon this chemical scaffold may be better tolerated in vivo.
Importantly, the compounds described herein weakly interact
with FABP3, which may be advantageous as previous work has
shown that mice lacking FABP3 develop age-dependent cardiac
hypertrophy [39].
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